A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de novo Kidney Transplant Recipients

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/135/31/13

Funding

  • Astellas Pharma Global Development Incorporated: $7,258.00